BTK
BTK (Bruton's tyrosine kinase) inhibitors are compounds that specifically target and inhibit BTK, a crucial enzyme involved in B-cell receptor signaling and the regulation of angiogenesis. BTK plays a significant role in the proliferation and survival of cancer cells, particularly in hematological malignancies. By inhibiting BTK, these compounds can disrupt angiogenesis and tumor growth, making them valuable in cancer therapy. At CymitQuimica, we offer a range of high-quality BTK inhibitors to support your research in oncology, immunology, and angiogenesis.
Found 175 products for "BTK".
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
ARQ 531
CAS:ARQ-531: potent oral BTK inhibitor, anti-cancer potential, IC50 of 0.85/0.39 nM for WT/C481S-BTK.Formula:C25H23ClN4O4Purity:98.68% - 99.63%Color and Shape:SolidMolecular weight:478.928AS-1763
CAS:AS-1763 is an orally available and selective BTK inhibitor with an IC50 of 0.85 nM.Formula:C33H31FN6O3Purity:≥95%Color and Shape:SolidMolecular weight:578.64IBT6A
CAS:IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.Formula:C22H22N6OPurity:99.88% - 99.88%Color and Shape:Yellow SolidMolecular weight:386.45Tirabrutinib hydrochloride
CAS:Tirabrutinib hydrochloride is a potent, highly selective, irreversible oral BTK inhibitor.Cost-effective and quality-assured.Formula:C25H23ClN6O3Purity:99.27% - 99.95%Color and Shape:White SolidMolecular weight:490.942MT-802
CAS:MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).Formula:C41H41N9O8Purity:95.93% - 97.60%Color and Shape:SolidMolecular weight:787.82Ref: TM-T16157
1mg92.00€5mg177.00€1mL*10mM (DMSO)231.00€10mg269.00€25mg510.00€50mg692.00€100mg888.00€200mg1,251.00€Rilzabrutinib
CAS:Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).Formula:C36H40FN9O3Purity:98.28% - 99.76%Color and Shape:White SolidMolecular weight:665.7597Ref: TM-T12542
1mg94.00€5mg222.00€1mL*10mM (DMSO)325.00€10mg356.00€25mg620.00€50mg893.00€100mg1,251.00€500mg2,502.00€Btk inhibitor 2
CAS:Btk inhibitor 2 (BGB-3111 analog) is a BTK inhibitor.Formula:C24H25N5O3Purity:99.94%Color and Shape:SolidMolecular weight:431.487Ref: TM-T10629
1mg34.00€2mg49.00€5mg74.00€1mL*10mM (DMSO)82.00€10mg98.00€25mg215.00€50mg356.00€100mg434.00€Acalabrutinib enantiomer
CAS:R-Acalabrutinib, a BTK inhibitor,enantiomer, is researched for cancer, autoimmune diseases, and inflammation.Formula:C26H23N7O2Purity:99.20%Color and Shape:SolidMolecular weight:465.5065Ref: TM-T67881
200mgTo inquire1mg80.00€5mg168.00€1mL*10mM (DMSO)178.00€10mg238.00€25mg379.00€50mg513.00€100mg707.00€Orelabrutinib
CAS:Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).Formula:C26H25N3O3Purity:97.77% - 99.54%Color and Shape:SolidMolecular weight:427.495Ref: TM-T12317
1mg86.00€5mg177.00€1mL*10mM (DMSO)205.00€10mg299.00€25mg492.00€50mg682.00€100mg897.00€500mg1,791.00€DD 03-171
CAS:Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.Formula:C55H62N10O8Color and Shape:SolidMolecular weight:991.163DFCI-002-06
CAS:DFCI-002-06 is an orally active dual-targeted HCK/BTK PROTAC degrader, demonstrating DC₅₀ values of 1.3 nM for HCK and 4.5 nM for BTK. It retains superior antitumor activity compared to dual-targeted HCK/BTK inhibitors and induces apoptosis in cancer cells. DFCI-002-06 is applicable in studies of MYD88-mutant B-cell malignancies.Formula:C44H46N10O5Molecular weight:794.92BRK inhibitor P21d hydrochloride
CAS:BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.Formula:C23H23ClFN7O2Color and Shape:SolidMolecular weight:483.93TLT8
TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.Color and Shape:Odour SolidFDU73
FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.Color and Shape:Odour SolidPROTAC BTK Degrader-2
CAS:PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].Formula:C47H54F2N8O13Color and Shape:SolidMolecular weight:976.97PROTAC BTK Degrader-1
CAS:Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.Formula:C43H43N9O4Color and Shape:SolidMolecular weight:749.86BTK-IN-5
CAS:BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,Formula:C23H32N4O5Color and Shape:SolidMolecular weight:444.532LFM-A13
CAS:LFM-A13 is a highly selective BTK inhibitor; IC50 2.5 uM; targets catalytic domain; severs BCR signaling; anti-leukemic; autoimmune disease and lymphocytic leukemia research.Formula:C11H8Br2N2O2Purity:99.50%Color and Shape:White SolidMolecular weight:360Ibrutinib dimer
CAS:Ibrutinib dimer is an impurity of Ibrutinib. IIbrutinib dimer is a Dimer of Ibrutinib. Ibrutinib is an irreversible Btk inhibitor (IC50: 0.5 nM).Formula:C50H48N12O4Purity:98%Color and Shape:SolidMolecular weight:880.99FDA-Approved Kinase Inhibitor Library
A unique collection of xnum kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.Color and Shape:LiquidRef: TM-L1610
1mgTo inquire10μL*10mM (DMSO)To inquire30μL*10mM (DMSO)To inquire50μL*10mM (DMSO)To inquire100μL*10mM (DMSO)To inquire
